Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Blocklisting Interim Review

17 Aug 2015 09:14

RNS Number : 2142W
GW Pharmaceuticals PLC
17 August 2015
 



 

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS APPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

119,050 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

72,150 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

46,900 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

516,558 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

200,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

200,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

122,613 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS UNAPPROVED SHARE OPTION SCHEME 2001

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

312,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

755,473 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

56,978 ORDINARY SHARES OF 0.1P EACH

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,279,192 ORDINARY SHARES OF 0.1P EACH ON 21 JULY 2004

500,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

800,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JANUARY 2015

500,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

BLOCKLISTING INTERIM REVIEW

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS EXECUTIVE SHARE OPTION SCHEME

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

208,550 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

2,800 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

205,750 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

1,388,375 ORDINARY SHARES OF 0.1P EACH ON 7 OCTOBER 2003

300,000 ORDINARY SHARES OF 0.1P EACH ON 23 APRIL 2008

400,000 ORDINARY SHARES OF 0.1P EACH ON 18 JANUARY 2010

400,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 24 MAY 2011

168,650 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

1. NAME OF COMPANY:

 

GW PHARMACEUTICALS PLC

 

2. NAME OF SCHEME:

 

GW PHARMACEUTICALS LONG TERM INCENTIVE PLAN 2008

 

3. PERIOD OF RETURN:

 

FROM: 18 FEBRUARY 2015 TO: 17 AUGUST 2015

 

4. NUMBER AND CLASS OF SHARES(S) (AMOUNT OF STOCK/DEBT SECURITY) NOT ISSUED UNDER SCHEME AT END OF THE LAST PERIOD:

 

784,451 ORDINARY SHARES OF 0.1P EACH

 

5. NUMBER OF SHARES ISSUED/ALLOTTED UNDER SCHEME DURING PERIOD:

 

1,021,408 ORDINARY SHARES OF 0.1P EACH

 

6. BALANCE UNDER SCHEME NOT YET ISSUED/ALLOTTED AT END OF PERIOD:

 

763,043 ORDINARY SHARES OF 0.1P EACH.

 

7. NUMBER AND CLASS OF SHARE(S) (AMOUNT OF STOCK/DEBT SECURITIES) ORIGINALLY LISTED AND THE DATE OF ADMISSION:

 

600,000 ORDINARY SHARES OF 0.1P EACH ON 23 FEBRUARY 2011

300,000 ORDINARY SHARES OF 0.1P EACH ON 29 NOVEMBER 2013

500,000 ORDINARY SHARES OF 0.1P EACH ON 9 JUNE 2014

1,000,000 ORDINARY SHARES OF 0.1P EACH ON 5 JUNE 2015

 

PLEASE CONFIRM TOTAL NUMBER OF SHARES IN ISSUE AT THE END OF THE PERIOD IN ORDER FOR US TO UPDATE OUR RECORDS.

 

261,087,473 ORDINARY SHARES OF 0.1P EACH

 

 

 

For further information, please contact:

 

Adam George, Company Secretary, GW Pharmaceuticals plc

 

Telephone: +44 (0)1223 266800

 

James Steel/Clare Terlouw, Nominated Adviser, Peel Hunt LLP

 

Telephone: +44 (0)20 7418 8900

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRVDLBFEVFFBBX
Date   Source Headline
27th Jan 20157:01 amRNSNotice of Results
9th Jan 20154:24 pmRNSBlock Listing Application
8th Jan 201512:00 pmRNSUpdate on Epidiolex Program
8th Jan 201512:00 pmRNSResults in Sativex Phase 3 Cancer Pain Trial
22nd Dec 20147:00 amRNSGW Added to NASDAQ Biotechnology Index
17th Dec 20146:16 pmRNSPublication of UK Annual Report and Accounts
17th Dec 20144:49 pmRNSDirector/PDMR Shareholding
3rd Dec 20148:22 amRNSHolding(s) in Company
2nd Dec 201412:00 pmRNSFinal Results
26th Nov 20147:00 amRNSGW Presents at Piper Jaffray Healthcare Conference
24th Nov 20147:00 amRNSNotice of Results
17th Nov 20143:00 pmRNSPresenting at Jefferies 2014 Healthcare Conference
30th Oct 20147:00 amRNSPhase 2/3 Trial of Epidiolex in Dravet Syndrome
22nd Oct 20147:00 amRNSEpidiolex Orphan Designation from EMA
14th Oct 201412:00 pmRNSResults of Phase 2a Ulcerative Colitis Trial
14th Oct 201412:00 pmRNSNew Physician Reports of Epidiolex Treatment
7th Oct 20149:45 amRNSAdditional Listing
29th Sep 20141:00 pmRNSGW Research and Development Day Details
24th Sep 20147:00 amRNSPresenting at Leerink Rare Disease Roundtable 2014
29th Aug 201412:20 pmRNSDirector/PDMR Shareholding
28th Aug 20147:00 amRNSPresenting at Upcoming Investor Conferences
18th Aug 201411:19 amRNSBlocklisting Interim Review
12th Aug 20144:32 pmRNSGrant of Options
6th Aug 20147:00 amRNSThird Quarter Financial Results
30th Jul 20147:00 amRNSNotice of Results
8th Jul 201410:18 amRNSHolding(s) in Company
30th Jun 20145:15 pmRNSHolding(s) in Company
30th Jun 20145:12 pmRNSHolding(s) in Company
30th Jun 20142:11 pmRNSHolding(s) in Company
25th Jun 20144:16 pmRNSClosing of U.S. Public Offering of ADSs on NASDAQ
24th Jun 20149:18 amRNSExercise of Underwriters' Option to Purchase ADSs
19th Jun 20147:00 amRNSPricing of U.S. Public Offering of ADSs
18th Jun 20147:00 amRNSProposed Public Offering of ADSs
17th Jun 201412:00 pmRNSEpidiolex IND Data
9th Jun 201412:34 pmRNSBlock Listing Application
6th Jun 20147:00 amRNSEpidiolex Fast Track Designation - Dravet Syndrome
29th May 20143:11 pmRNSHolding(s) in Company
8th May 20145:00 pmRNSPresenting at BAML 2014 Health Care Conference
7th May 20147:02 amRNSHalf Yearly Report
7th May 20147:00 amRNSIND for Epidiolex Ph 2/3 Trial in Dravet Syndrome
6th May 20145:54 pmRNSHolding(s) in Company
6th May 20147:01 amRNSAppointment of VP, Clinical Science
29th Apr 20145:30 pmRNSNotice of Results
28th Apr 20141:46 pmRNSHolding(s) in Company
28th Apr 20147:00 amRNSSativex FDA Fast Track Designation in Cancer Pain
19th Mar 20143:24 pmRNSHolding(s) in Company
17th Mar 20147:00 amRNSUpdate on Cannabinoid Pipeline
11th Mar 20142:34 pmRNSAnnual General Meeting
28th Feb 20141:00 pmRNSFDA Orphan Drug Designation received for Epidiolex
27th Feb 20147:00 amRNSGW to Present at Cowen Health Care Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.